DOuble SEquential External Defibrillation for Refractory VF

NCT04080986 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 405

Last updated 2022-09-22

No results posted yet for this study

Summary

Despite significant advances in resuscitation efforts, there are some patients who remain in refractory ventricular fibrillation (VF) during out-of-hospital cardiac arrest. Double sequential external defibrillation (DSED) and vector change defibrillation have been proposed as viable options for patients in refractory VF. This cluster randomized trial will compare (1) continued resuscitation using standard defibrillation; (2) resuscitation involving DSED; or (3) resuscitation involving vector change defibrillation, in patients presenting with refractory VF during out-of-hospital cardiac arrest. The results of this study will provide high level evidence of the impact of both DSED and vector change defibrillation on ROSC and patient survival after OHCA.

Conditions

  • Out-Of-Hospital Cardiac Arrest
  • Ventricular Fibrillation

Interventions

PROCEDURE

Double Sequential Defibrillation

Defibrillation using pad placement in anterior-posterior position

PROCEDURE

Vector Change Defibrillation

Defibrillation using two defibrillators, one with pad placement in anterior-posterior position and the other with pad placement in anterior-anterior position delivering two rapid sequential shocks.

Sponsors & Collaborators

  • Peel Regional Paramedic Services

    collaborator UNKNOWN
  • Toronto Paramedic Services

    collaborator UNKNOWN
  • Halton Region Paramedic Services

    collaborator OTHER
  • County of Simcoe Paramedic Services

    collaborator UNKNOWN
  • London Health Sciences Centre

    collaborator OTHER
  • Middlesex-London EMS

    collaborator UNKNOWN
  • Ottawa Paramedic Service

    collaborator UNKNOWN
  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Sheldon Cheskes, MD · Sunnybrook Centre for Prehospital Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-10
Primary Completion
2022-08-01
Completion
2022-08-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04080986 on ClinicalTrials.gov